American Academy of Neurology annual meeting – 13-18 April 2024
The following summarizes some of the highlights from Day 1 of AAN 2024.
Latest News
Elevated sNfL a possible biomarker of recent seizure in epilepsy
April 5, 2024Neurofilament-light (NfL) chain is emerging as an important biomarker of neuroaxonal injury in multiple sclerosis, Alzheimer disease, spinal cord injury and other neurological disorders, but has been less studied in epilepsy. Read More
Fluid biomarkers: theory and practice
March 18, 2024ACTRIMS Forum 2024
Considerable progress has been made in recent years in determining the place in therapy of fluid biomarkers of multiple sclerosis and other neurological disorders. Among the most studied are neurofilament-light chain (NfL), a marker of neuroaxonal damage, and glial fibrillary acidic protein (GFAP), a marker of astrogliosis. The following summarizes fluid biomarker studies presented at the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum, held February 29 to March 2, 2024, in West Palm Beach, Florida. Read More
Evobrutinib in MS – ACTRIMS Forum update
March 11, 2024Merck KGaA announced in December the top-line results of its failed phase III trials of evobrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, but few details were available at that time. Full results have now been presented by Dr. Xavier Montalban, Barcelona, Spain, at the ACTRIMS Forum conference, held February 29-March 2 in West Palm Beach, Florida. Read More